MedTrace Logo

VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)

NCT00727753 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2015-05-28

No results posted yet for this study

Summary

The objective of this study is to evaluate the effects of 2 intravitreal injections with Ranibizumab or Avastin on endothelial function in subjects with neovascular macular degeneration compared to patients with dry AMD.

Conditions

  • Macular Degeneration

Interventions

DRUG

Ranibizumab

ranibizumab (0.5 mg) will be injected intraocular

DRUG

Bevacizumab

Bevacizumab (1.25 mg) will be injected intraocular

OTHER

No treatment

No treatment

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Frank Ruschitzka, Prof MD · University Hospital Zurich, Division of Cardiology

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2012-12-31
Completion
2013-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00727753 on ClinicalTrials.gov